81 related articles for article (PubMed ID: 21459491)
1. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies.
Cavdar H; Senturk M; Guney M; Durdagi S; Kayik G; Supuran CT; Ekinci D
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):429-437. PubMed ID: 30734597
[TBL] [Abstract][Full Text] [Related]
3. Identification of Potent and Selective Acetylcholinesterase/Butyrylcholinesterase Inhibitors by Virtual Screening.
Xu T; Li S; Li AJ; Zhao J; Sakamuru S; Huang W; Xia M; Huang R
J Chem Inf Model; 2023 Apr; 63(8):2321-2330. PubMed ID: 37011147
[TBL] [Abstract][Full Text] [Related]
4. Identification of Compounds for Butyrylcholinesterase Inhibition.
Li S; Li AJ; Travers J; Xu T; Sakamuru S; Klumpp-Thomas C; Huang R; Xia M
SLAS Discov; 2021 Dec; 26(10):1355-1364. PubMed ID: 34269114
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, in vitro and in silico evaluations of new isatin-triazine- aniline hybrids as potent anti- Alzheimer multi-target directed lead compounds.
Tamaddon-Abibigloo Y; Dastmalchi S; Razzaghi-Asl N; Shahbazi Mojarrad J
Bioorg Chem; 2024 Jun; 147():107355. PubMed ID: 38657528
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro cholinesterase inhibitory potential of dihydropyridine derivatives.
Zafar AM; Iqbal A; Ashraf M; Aslam S; Naureen S; Aslam N; Jabeen M; Sajid N; Ghafoor A; Noreen S; Shahi MN; Khan MA
Pak J Pharm Sci; 2019 May; 32(3 (Supplementary)):1155-1162. PubMed ID: 31303584
[TBL] [Abstract][Full Text] [Related]
7. New 3-amino-2-thioxothiazolidin-4-one-based inhibitors of acetyl- and butyryl-cholinesterase: synthesis and activity.
Krátký M; Nováčková K; Svrčková K; Švarcová M; Štěpánková Š
Future Med Chem; 2024 Jan; 16(1):59-74. PubMed ID: 38047370
[No Abstract] [Full Text] [Related]
8. Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.
Pajk S; Knez D; Košak U; Zorović M; Brazzolotto X; Coquelle N; Nachon F; Colletier JP; Živin M; Stojan J; Gobec S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):498-505. PubMed ID: 31914836
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterases and the fine line between poison and remedy.
Pope CN; Brimijoin S
Biochem Pharmacol; 2018 Jul; 153():205-216. PubMed ID: 29409903
[TBL] [Abstract][Full Text] [Related]
10. Discovery, Structure-Based Modification,
Lu X; Li Y; Guan Q; Yang H; Liu Y; Du C; Wang L; Wang Q; Pei Y; Wu L; Sun H; Chen Y
ACS Chem Neurosci; 2024 Mar; 15(6):1135-1156. PubMed ID: 38453668
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.
Williams A; Zhou S; Zhan CG
Bioorg Med Chem Lett; 2019 Dec; 29(24):126754. PubMed ID: 31708262
[TBL] [Abstract][Full Text] [Related]
12. Sequential Contrastive and Deep Learning Models to Identify Selective Butyrylcholinesterase Inhibitors.
Ozalp MK; Vignaux PA; Puhl AC; Lane TR; Urbina F; Ekins S
J Chem Inf Model; 2024 Apr; 64(8):3161-3172. PubMed ID: 38532612
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease.
Gao J; Midde N; Zhu J; Terry AV; McInnes C; Chapman JM
Bioorg Med Chem Lett; 2016 Nov; 26(22):5573-5579. PubMed ID: 27769620
[TBL] [Abstract][Full Text] [Related]
14. N-methylated diazabicyclo[3.2.2]nonane substituted triterpenoic acids are excellent, hyperbolic and selective inhibitors for butyrylcholinesterase.
Heise N; Friedrich S; Temml V; Schuster D; Siewert B; Csuk R
Eur J Med Chem; 2022 Jan; 227():113947. PubMed ID: 34731766
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (BChE) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer's Disease.
Wang L; Sun T; Wang Z; Liu H; Qiu W; Tang X; Guo H; Yang P; Chen Y; Sun H
ACS Chem Neurosci; 2023 Sep; 14(17):3226-3248. PubMed ID: 37561893
[TBL] [Abstract][Full Text] [Related]
16. Phenyl-quinoline derivatives as lead structure of cholinesterase inhibitors with potency to reduce the GSK-3β level targeting Alzheimer's disease.
Noori M; Dastyafteh N; Safapoor S; Khalili Ghomi M; Tanideh R; Zomorodian K; Hamedifar H; Dara M; Zare S; Irajie C; Javanshir S; Rastegar H; Panahi N; Larijani B; Mahdavi M; Hajimiri MH; Iraji A
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127392. PubMed ID: 37827412
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine-Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors.
Wu J; Tan Z; Pistolozzi M; Tan W
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202655
[TBL] [Abstract][Full Text] [Related]
18. The structural modification and biological evaluation of tetrahydrothienopyridine derivatives as selective BChE inhibitors.
Chen T; Sang S; Wei Y; Ge Y; Jin J; Bian Y; Pei Y; Li N; Sun H; Chen Y
Bioorg Med Chem Lett; 2023 Sep; 93():129436. PubMed ID: 37549853
[TBL] [Abstract][Full Text] [Related]
19. Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity.
Bosak A; Knežević A; Gazić Smilović I; Šinko G; Kovarik Z
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):789-797. PubMed ID: 28573890
[TBL] [Abstract][Full Text] [Related]
20. Optimizing drug-like properties of selective butyrylcholinesterase inhibitors for cognitive improvement: Enhancing aqueous solubility by disrupting molecular plane.
Xing S; Tang X; Wang L; Wang J; Lv B; Wang X; Guo C; Zhao Y; Feng F; Liu W; Chen Y; Sun H
Eur J Med Chem; 2024 Mar; 268():116289. PubMed ID: 38452730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
